2. UroToday Home
  3. Categories

Bladder Cancer

Cost-effectiveness of de-escalated molecular subtype dependent use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer in a Swedish setting.

Guidelines recommend neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC). Current recommendations do not consider genomic profiles, although the Basal/Squamous (Ba/Sq) subtype is less likely to respond to NAC compared to Urothelial-like (Uro) and Genomically Unstable (GU) subtypes.

The impact of treatment for muscle-invasive bladder cancer on health-related quality of life.

To evaluate the impact of treatment for localised muscle-invasive bladder cancer (MIBC) during the first 2 years after diagnosis.

A prospective cohort study was conducted including patients diagnosed with non-metastatic (cM0) MIBC between November 2017 and November 2019 in the Netherlands.

Perioperative outcomes using template mapping after radical cystectomy and extended lymph node dissection.

To evaluate oncologic and perioperative outcomes of extended pelvic lymph node dissection (PLND) during robot-assisted radical cystectomy (RARC) based on the location of lymph node positivity (LN+).

Circulating tumour DNA and circulating tumour cells in bladder cancer - from discovery to clinical implementation.

Liquid biopsies, indicating the sampling of body fluids rather than solid-tissue biopsies, have the potential to revolutionize cancer care through personalized, noninvasive disease detection and monitoring.

Performance Large Language Models in Guiding Bladder Cancer Management - Expert Commentary

Bladder cancer (BLCA) management presents complex clinical challenges requiring deep knowledge of current guidelines and clinical expertise. A recent study by Li et al. evaluated the performance of several large language models (LLMs) in addressing clinical management questions related to bladder cancer.

Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?

Due to unclear evidence of survival improvement, this study aimed to evaluate the efficacy of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real-world clinical practice in Japan.

We initially extracted patients who underwent open radical cystectomy between July 2000 and May 2021 at Kanazawa University Hospital from the medical charts, and we selected patients diagnosed with pure urothelial carcinoma.

Loss of chromosome Y is unrelated to the composition of the tumor microenvironment and patient prognosis in muscle-invasive urothelial bladder cancers.

Loss of chromosome Y (LOY) has recently been proposed to be associated with cancer aggressiveness, altered T-cell function, and poor prognosis in bladder carcinomas.

Chromosome Y was analyzed using fluorescence in-situ hybridization on a tissue microarray containing 2,071 urothelial carcinomas of the urinary bladder from male patients, including 487 patients who had undergone cystectomy for muscle-invasive disease and for whom follow-up data were available.

ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia

Company to Provide Regulatory, Sales, and Platform Updates at Investor Day including:

  • In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
  • In Q2, the company submitted to the U.S. Food and Drug Administration (FDA) an Expanded Access Protocol (EAP) for ANKTIVA for the treatment of lymphopenia as a BioShield against the adverse effects of chemotherapy, radiation and checkpoint inhibitors, following authorization of a Regenerative Medicine Advanced Therapy (RMAT) designation for this indication in Q1.

Prognostic impact of combined loss of RB1, p53 and p21 in muscle-invasive bladder cancer.

Muscle-invasive bladder cancer (MIBC) represents a genetically heterogeneous disease with limited prognostic markers. This study aimed to validate the prognostic relevance of combined alterations in cell cycle regulators RB1, p53, and p21 in a broad cohort of MIBC patients undergoing radical cystectomy (RC).

Integration and evaluation of implementation strategies to improve guideline-concordant bladder cancer surveillance: a prospective observational study.

Despite guideline recommendations, our prior work revealed more than half of low-risk bladder cancer patients within the Department of Veterans Affairs (VA) undergo too many surveillance procedures and about a third of high-risk patients do not undergo enough procedures.

Page 1 of 1119